Background and Objectives: Individuals with type 2 diabetes mellitus (T2DM) have an
increased risk of cardiovascular disease. Arterial stiffness is an independent prognostic …

Background Empagliflozin has been shown to reduce cardiovascular mortality, but the
underlying pathogenetic mechanisms are poorly understood. It was previously …

We investigated the effect of additional treatment with newer antidiabetic drugs on
endothelium function and arterial stiffness in subjects with type 1 diabetes mellitus (T1DM) …

Background Deteriorated arterial function and high incidence of cardiovascular events
characterise diabetes mellitus. Metformin and recent antidiabetic drugs, SGLT2 inhibitors …

Background Pulse wave velocity (PWV) and augmentation index (AIx) are indices used to
assess arterial stiffness. We aim to compare the effect of empagliflozin, liraglutide and their …

Background Individuals with type 1 diabetes mellitus are at high risk for the development of
hypertension, contributing to cardiovascular complications. Hyperglycaemia-mediated …

Introduction Oral antidiabetic inhibitors of the sodium-glucose cotransporter (SGLT2i) reduce
cardiovascular morbidity and mortality in DM2. The increase in arterial stiffness can …

Controlling the blood glucose level is of outmost importance for the prevention of the micro-
and macrovascular diabetic complications observed in patients with type 1 diabetes (T1D) …

Aims To determine the effects of empagliflozin on blood pressure (BP) and markers of
arterial stiffness and vascular resistance in patients with type 2 diabetes mellitus (T2DM) …

Background Cardiovascular protection following empagliflozin therapy is not entirely
attributable to the glucose lowering effect. Increased hematocrit might influence the shear …